Estrogen receptors have protective effects against ischemic brain injury. However, the molecular mechanisms underlying this phenomenon have yet to be well studied. Given that inhibition of glycogen synthase kinase (GSK3) can reduce cerebral ischemia/reperfusion injury, we hypothesized that estrogen receptors-mediated protective effects against ischemia-induced blood-brain barrier (BBB) disruption involve inhibition of GSK3. Thus, we evaluated GSK3 expression in the brain of ovariectomized female rats, and examined the effects of intracerebroventricular pre-treatments of SB216763, GSK3 inhibitor, on BBB permeability following middle cerebral artery occlusion (MCAO). We also examined the role of specific estrogen receptor subtype in regulation of GSK3 expression and BBB permeability after MCAO. We found that ovariectomized female rats exhibited increased mRNA levels of estrogen receptor a (ERa) and estrogen receptor b (ERb), and increased protein levels of GSK3b but not GSK3a in brain cortical areas. Furthermore, intracerebroventricular pre-treatments of SB216763 dose-dependently attenuated brain infarction volume, brain water contents, neurological deficits, and BBB disruption, and increased tight junction protein ZO-1 and occludin expression at 24 h following MCAO. Finally, activation of ERb but not ERa dose-dependently decreased GSK3b expression at 24 h following MCAO. This was associated with increased tight junction protein expression and improved neurological scores. Thus, our study suggested that activation of ERb may protect against brain ischemia-induced BBB disruption by inhibiting GSK3b-mediated signaling.
The incidence of stroke increases substantially with aging, and around one-third of ischemic strokes occur in elderly populations (Lamb et al. 2003; Slemmer et al. 2008) . Importantly, human studies have demonstrated that premenopausal women have a lower incidence of stroke and cardiovascular disease compared to post-menopausal women, suggesting that estrogen may play a critical role in protection against ischemic stroke in women (Mikkola et al. 2015; Holmegard et al. 2016) . Consistently, animal studies have shown that ovariectomy in female animals resulted in an increased ischemic injury that could be reversed by exogenous administration of estrogen (Medina et al. 2003; Ma et al. 2016) . While studies have indicated that estrogen receptors (ERs) a and b are both involved in the protective effects of estrogen on ischemic brain injury (Broughton et al. 2014; Madinier et al. 2014; Cue et al. 2015; Zou et al. 2015) , the molecular mechanisms underlying such an effect have yet to be well studied.
Animal studies have demonstrated that estrogen has potent neuroprotective effects in brain ischemia, and estrogenmediated neuroprotective effects are dependent on activation of ERs. Specifically, estrogen replacement therapy in ovariectomized female rodents can reduce ischemia-induced brain tissue damage, which is mitigated by inhibition of ERs (Sawada et al. 2000; Miller et al. 2005) . Furthermore, using ERs subtype-selective agonists in animal models of brain ischemia, and it has been shown that both ER a and ERb agonists can reduce ischemic brain damage (Carswell et al. 2004; Miller et al. 2005; Connell and Saleh 2011) . However, studies have also shown that both receptor subtypes have overlapping but unique roles in estrogen-dependent action in vivo due to their different transcriptional activities (Matthews and Gustafsson 2003; Marino et al. 2006; Vrtacnik et al. 2014) . Hence, it will be important to examine the underlying molecular mechanisms of ERa and ERb in the protective effects against brain ischemia.
It has been well recognized that breakdown of the bloodbrain barrier (BBB) is critically involved in the pathogenesis of stroke (Guell and Bix 2014; Kassner and Merali 2015) . During a major ischemic stroke, BBB disruption can lead to extravasation of solutes and fluids into the brain, resulting in vasogenic edema (Sandoval and Witt 2008) , which causes a poor clinical outcome in patients with ischemic stroke. Importantly, one of the neuroprotective effects of estrogen is to reduce BBB breakdown after ischemic stroke. For instance, animal studies have shown that estrogen replacement therapy can prevent BBB disruption and vasogenic edema induced by focal ischemia in ovariectomized rats (Shi et al. 2001; Chi et al. 2002 Chi et al. , 2006 Liu et al. 2005) . This phenomenon could be dependent on the activation of ERs. To support this, it has been demonstrated that estrogen treatment can increase the expression of claudin-5, a tight junction protein of the BBB, and that activation of ERb but not ERa can increase the expression of claudin-5 in ovariectomized mice (Burek et al. 2010) .
Importantly, ER-mediated up-regulation of tight junction proteins might involve the activation of glycogen synthase kinase (GSK) 3. Specifically, studies have shown that estradiol can produce a long-lasting inhibition of GSK3 activity in the adult female rat brain in vivo (Cardona-Gomez et al. 2004) , and inhibition of GSK3 can result in an increase in the expression level of tight junction proteins (Ramirez et al. 2013) . Furthermore, increasing evidence has shown that inhibition of GSK3 can reduce cerebral ischemia/ reperfusion injury (Chen et al. 2016; Li et al. 2016; Pang et al. 2016) . Therefore, this study was designed to examine the role of GSK3 in ER-mediated protective effects against ischemia-induced BBB disruption. To this end, we first evaluated the expression of GSK3 in the brain of ovariectomized female rats. We then evaluated the effects of intracerebroventricular injections of SB216763, a selective GSK3 inhibitor, on the BBB permeability following middle cerebral artery occlusion (MCAO) induced brain ischemia in ovariectomized female rats. Finally, we examined the role of specific ER subtype in regulation of GSK3 expression and BBB permeability following MCAO-induced brain ischemia in ovariectomized female rats.
Material and methods

Animals
Female Sprague-Dawley rats (24 months old) were purchased from Shanghai Laboratory Animal Center, and were acclimated in the Animal Center of The Second Xiangya Hospital, Central South University for 1 week before subsequent experiments. Rats were housed in a room with a 12 : 12 light cycle, and were given food and water ad libitum. All animal experiments were approved by the Institutional Animal Care and Use Committee of The Second Xiangya Hospital, Central South University. The housing and treatment of the rats followed the guidelines of the 'Guide for the Care and Use of Laboratory Rats' (Institute of Laboratory Animal Resources, Commission on Life Sciences 2011).
Surgery
Ovariectomy (OVX) surgery was conducted first. Briefly, rats were anesthetized using halothane (4% for induction, 2% for maintenance) and the ovaries were removed bilaterally through a dorsal incision using standard aseptic procedures. The incision was then closed using 9-mm stainless steel surgical staples (EZ clips; Stoelting Co., Wood Dale, IL, USA). Serum estradiol level was measured by radioimmunoassay (Cayman Chemical, shanghai, China) before and 2 weeks after ovariectomy surgery. Generally, pre-OVX estradiol level was 57.8 AE 7.6 pg/mL, and post-OVX level was 13.6 AE 0.4 pg/mL.
Immediately after ovariectomy surgery, some rats were placed in a stereotaxic apparatus (Stoelting). The scalp was first incised, and the skull was leveled off around the bregma. Permanent 26-gauge stainless steel guide cannulae (Plastics One, Roanoke, VA, USA) were positioned in the lateral ventricle using stereotactic coordinates (0.6 mm posterior to the bregma, 1.6 mm lateral to midline, and 4.0 mm below the outer surface of the skull). The cannulae were then fixed to the skull using three screws and dental acrylic. To keep cannulae patent prior to microinjection, a stainless steel obturator (Plastics One), was inserted to maintain cannula patency. Following surgery, rats received analgesic (acetaminophen; 100 mg/kg, s.c.) and penicillin G (0.1 mL/rat, i.m.). Saline was also administered to rehydrate the animals (1.5 mL/rat, s.c.). The health of each rat was monitored daily following surgery. All animals were allowed 7 days to recover from surgery.
Intracerebroventricular injection
Intracerebroventricular injection was conducted using a 28-gauge 12.5-mm injection needle, which was attached to a 30-cm polyethylene tube fitted to a 5 lL Hamilton syringe. The volume of solutions to be injected into the lateral ventricle was 2 lL and the injection was done over a period of 2 min. The doses of propyl pyrazole triol (PPT, 10, 50 nmol/lL, selective ERa receptor agonist), diarylpropionitrile (DPN, 10, 50 nmol/lL, selective ERb receptor agonist), and SB216763 (10, 100 pmol/lL, selective GSK3 inhibitor) used in the experiments were based on previous studies (Chan et al. 2008 (Chan et al. , 2012 Xue et al. 2013 ) and pilot studies. Intracerebroventricular administration was chosen to avoid any peripheral estrogen effects on cardiovascular function during repeated treatment. PPT, DPN, and SB216763 (Tocris, Shanghai, China) was dissolved in 1% dimethyl sulfoxide and diluted in artificial cerebrospinal fluid containing NaCl (120 mM), KCl (5 mM), CaCl 2 (1.5 mM), MgCl 2 (0.8 mM), Na 2 HPO 4 (1.4 mM), and NaH 2 PO 4 (0.25 mM) at pH 7.4. Control rats received 5 lL 1% dimethyl sulfoxide in artificial cerebrospinal fluid.
Middle cerebral artery occlusion MCAO was introduced in rats using intraluminal monofilament techniques as described previously (Wu et al. 2015) . Briefly, after surgically exposing the left common carotid artery, the internal carotid artery, and the external carotid artery in anesthetized rats, a 4-0 nylon monofilament suture was inserted through the external carotid artery and forward into the internal carotid artery to induce MCA occlusion for 2 h. The ischemia was evaluated by laser Doppler perfusion imaging, as a reduced regional cerebral blood flow > 80%. Reperfusion (a return to > 7% of the baseline within 10 min of suture withdrawal) was achieved by withdrawing the nylon suture. Shamoperated rats received the same surgery process without the MCAO.
Bederson neurological scores
Twenty-four hours after MCAO, behavior was assessed by independent observers in a blinded fashion based on a 5-point scale system as previously described (Yang et al. 2014) : 0, no obvious neurological deficits; 1, unable to fully extend the contralateral forelimb; 2, failure of walking straight or circling to the ipsilateral side; 3, leaning towards the affected side; 4, no spontaneous locomotor activity; 5, death.
Evaluation of brain infarction volume
Brain infarction was evaluated in rats 24 h after MCAO using 2,3,5-triphenyltetrazolium chloride staining, based on a published protocol (Joshi et al. 2004) . Rats brains were harvested and cut into four 2-mm thick slices, followed by 1% 2,3,5-triphenyltetrazolium chloride (Sigma, St. Louis, MO, USA) stain at 37°C. Brain slices were fixed in 10% neutral buffered formalin solution (Sigma), and the necrotic areas were identified by color change. The size and extent of the infarction was then determined and quantified by Image J (NIH, Bethesda, MD).
Brain water content assessment
Separate groups of rats were sacrificed 24 h after MCAO and the brains were harvested and cutted into the left and right hemispheres. Both hemispheres were weighed before (wet weight) and after an oven dry at 80°C overnight (dry weight). The percentage of the water contents were then calculated as [(wet weight À dry weight)/ wet weight] 9 100%.
Determination of Evans blue dye extravasation
To evaluate the integrity of the BBB, Evans blue dye was used as a marker of albumin extravasation, based on the method modified from a published protocol (Kaya and Ahishali 2011) . Briefly, Evans blue dye (2% in saline, 4 mL/kg) was injected via the tail vein at 24 h after MCAO and allowed to remain in circulation for 2 h. Rats were then perfused transcardially using saline. The brains were collected and imaged. The quantitative measurement of EB-albumin extravasation was then conducted using brain homogenates (2.5 mL phosphate-buffered saline followed by the addition of 2.5 mL of 60% trichloroacetic acid). Samples were cooled and then centrifuged for 30 min at 1000 g. The supernatant was measured at 610 nm for absorbance of Evans blue dye using a spectrophotometer against a standard curve. EB was expressed as mg/g of brain tissue.
Quantitative PCR mRNA expressions of tight junction proteins were measured using quantitative PCR in the brain tissues collected 24 h after MCAO. Total RNA was extracted by Trizol (Invitrogen, Carlsbad, CA, USA) and reverse transcribed into cDNA using kits (Applied Biosystems, Waltham, MA, USA). The qPCR primers were listed in Table 1 . The PCR reactions were performed by cyber green-based system (Applied Biosystems), and the expression levels were normalized to b-actin and expressed as relative levels to sham controls.
Western blotting
The protein samples were harvested from the ipsilateral cortex of the animals receiving MCAO and measured by bicinchoninic acid assay kits (Thermo Fisher, Waltham, MA, USA). A quantity of 40 lg of total protein was subjected to 7-10% sodium dodecyl sulfatepolyacrylamide gel electrophoresis, and was transferred to nitrocellulose membranes using a Bio-Rad Trans-Blot apparatus; Bio-Rad Laboratories, Hercules, CA, USA at 100 V for 2 h. The membranes were blocked with 5% non-fat dried milk in 0.01 M phosphatebuffered saline for 2 h, probed with antibodies against GSK3a (1 : 1000, ab40870, RRID:AB_732666; Abcam, Cambridge, MA, USA), GSK3b (1 : 1000, ab32391, RRID:AB_2115066; Abcam), pGSK3b (Ser9; 1 : 1000, Cat# 9336, RRID:AB_331405; Cell Signaling Technology, Beverly, MA, USA), ZO-1 (1 : 2000, ab61357, RRID:AB_2205519; Abcam), occludin (1 : 2000, ab31721, RRID:AB_881773; Abcam), and b-actin (RRID: AB_476693; Sigma). Protein levels were examined using an enhanced chemiluminescence-based detection system. Protein bands were analyzed by ImageJ as normalized with b-actin.
Statistical analysis
The sample size in each experiment was determined based our previous studies and power analysis showed that power was at least 0.84. Data were expressed as mean AE standard deviation 
Results
Effects of ovariectomy on protein levels of GSK3a and GSK3b in the cortical regions in aged female rats The experimental procedures in this study were shown in Fig. 1 . We found that ovariectomized female rats exhibited increased protein levels of GSK3b but not GSK3a in cortical areas of the brain ( Fig. 2 ; t-test, p < 0.05).
Effects of repeated intracerebroventricular injections of SB216763 on brain infarction, water contents, and neurological scores in aged ovariectomized female rats To examine the role of GSK3 in the regulation of brain ischemia-induced behavioral and neurological deficits, we intracerebroventricularly injected SB216763, a potent GSK3 inhibitor, for six consecutive days. We found that MCAO increased brain infarction volume, brain water contents, and neurological deficits in aged ovariectomized female rats ( Fig. 3 ; All one-way ANOVA, F (3,36) = 28.79, p = 0.001-0.012). Furthermore, intracerebroventricular pre-treatments of 100 pmol/lL SB216763, but not 10 pmol/lL SB216763, attenuated brain infarction volume, decreased brain water contents, and reduced neurological deficits at 24 h following MCAO, as compared to vehicle ( Fig. 3 ; Tukey test, p < 0.05).
Effects of intracerebroventricular pre-treatment of SB216763 on MCAO-induced BBB disruption
We found that MCAO increased Evans blue leakage in the brains in aged ovariectomized female rats (one-way ANOVA, F (3,36) = 35.14, p < 0.001). Furthermore, intracerebroventricular pre-treatments of 100 pmol/lL SB216763, but not 10 pmol/lL SB216763, attenuated Evans blue leakage into Fig. 1 Experimental outline. Aged female rats were ovariectomized 2 weeks before biochemical analysis of glycogen synthase kinase (GSK)3a and GSK3b expression in the cortical regions of the brains 1 . Separate groups of rats were given intracerebroventricular injections (i.e. ICV) of propyl pyrazole triol [10, 50 nmol/lL, selective estrogen receptor (ER)a receptor agonist], diarylpropionitrile (10, 50 nmol/lL, selective ERb receptor agonist), or SB216763 (10, 100 pmol/lL, selective GSK3 inhibitor) for 6 days before middle cerebral artery occlusion (MCAO). Twenty-four hours after MCAO, behavioral, histological, and biochemical examinations were performed 2 . Fig. 2 Effects of ovariectomy on glycogen synthase kinase (GSK) and estrogen receptors. Protein levels of (a) GSK3a and (b) GSK3b, and mRNA levels of (c) Estrogen receptor (ER)a and (d) ERb in the cortical regions of the brains in aged female rats (n = 8/group) at 2 weeks after ovariectomy surgery. *p < 0.05 compared to non-ovariectomized sham controls. Fig. 3 Effects of repeated intracerebroventricular injections of SB216763 on brain infarction, water contents, and neurological scores in aged ovariectomized female rats at 24 h following middle cerebral artery occlusion (MCAO). SB216763 was administrated (10, 100 pmol/ lL, i.c.v) every day for six consecutive days before MCAO. Cerebral injuries were characterized by (a) brain infarct volume, (b) representative 2,3,5-triphenyltetrazolium chloride staining (c) brain water content, and (d) neurological scores. n = 10 in each group. *p < 0.05 compared to non-ovariectomized sham controls. ipsilateral brains of rats at 24 h following MCAO, as compared to vehicle ( Fig. 4 ; Tukey test, p < 0.05).
Effects of intracerebroventricular pre-treatment of SB216763 on the MCAO-induced loss of tight junction proteins We found that MCAO decreased mRNA expression of ZO-1 and occludin in the brains in aged ovariectomized female rats, as compared to sham controls ( Fig. 5a ; all one-way ANOVA, F (3,36) = 29.06-38.71, p = 0.001-0.018). However, intracerebroventricular pre-treatments of either 10 or 100 pmol/lL SB216763 did not alter mRNA expression of ZO-1 and occludin in the brains in aged ovariectomized female rats, as compared to vehicle (Fig. 5a) . Similarly, we found that MCAO decreased protein expression of ZO-1 and occludin in the brains in aged ovariectomized female rats, as compared to sham controls ( Fig. 5b and c ; all one-way ANOVA, F (3,36) = 27.69-33.11, p = 0.001-0.011). Furthermore, intracerebroventricular pre-treatments of 100 pmol/lL SB216763, but not 10 pmol/lL SB216763 enhanced protein levels of ZO-1 and occludin in the brains in aged ovariectomized female rats, as compared to vehicle ( Fig. 5b and c ; Tukey test, p < 0.05).
Effects of intracerebroventricular pre-treatment of PPT or DPN on the MCAO-induced loss of tight junction proteins and GSK3b and pGSK3b protein levels in aged ovariectomized female rats Replicating our previous results, we found that MCAO decreased protein expression of ZO-1 and occludin in the brains in aged ovariectomized female rats, as compared to sham controls (Fig. 6a, b , and d; all one-way ANOVA, F (3,36) = 23.96-31.07, p = 0.002-0.013). Furthermore, intracerebroventricular pre-treatments of PPT or DPN dosedependently enhanced protein levels of ZO-1 and occludin in the brains in aged ovariectomized female rats, as compared to vehicle (Fig. 6a, b , and d; Tukey test, p < 0.05) in a similar pattern. These effects were associated with the attenuation of neurological deficits (Fig. 7c ) and brain infarction volume ( Fig. 7a and b ) in rats at 24 h following MCAO. Similarly, MCAO induced an increase in GSK3b protein levels and a decrease in pGSK3b/GSK3b ratio in aged ovariectomized female rats, as compared to sham controls (Fig. 6c, and d ; all one-way ANOVA, F (3,36) = 24.63-30.75, p = 0.001-0.003). However, intracerebroventricular pre-treatments of the same dose of DPN, but not PPT, dose-dependently attenuated GSK3b protein levels and increased pGSK3b/GSK3b ratio in aged ovariectomized female rats, as compared to vehicle ( Fig. 6c and d ; Tukey test, p < 0.05).
Discussion
The present study was designed to investigate the role of GSK3 in ER-mediated protective effects against ischemia-induced BBB disruption. To this end, we first demonstrated that aged female rats exhibited increased mRNA levels of ERa and ERb, and increased protein levels of GSK3b but not GSK3a in brain cortical areas at 2 weeks following ovariectomy surgery. This result suggested that estrogen may exert an inhibitory control over GSK3b protein expression. Following these findings, we also demonstrated that intracerebroventricular pre-treatments of SB216763, a potent GSK3 inhibitor, dose-dependently attenuated brain infarction volume, brain water contents, and neurological deficits. This phenomenon was likely as a result of the protective effects of SB216763 on BBB integrity following MCAO in ovariectomized female rats. To support this hypothesis, we showed that intracerebroventricular pretreatments of SB216763 were able to increase tight junction protein ZO-1 and occludin expression, and attenuate Evens blue leakage at 24 h following MCAO. Finally, we found that activation of ERb but not ERa dose-dependently decreased GSK3b expression and pGSK3b/GSK3b ratio at 24 h following MCAO. Such a phenomenon was associated with increased tight junction protein expression and improved neurological scores in ovariectomized female rats. Taken together, our study suggested that activation of ERb may protect against brain ischemia-induced BBB disruption by promoting GSK3b-mediated signaling. GSK3b is a serine/threonine kinase, which plays a critical role in regulation of cell division, differentiation, apoptosis, signal transduction, and inflammation (Klamer et al. 2010 ). While our study has shown that ovariectomy in aged female rats could result in an increased expression of GSK3b, but not GSK3a, in the brain, it is still unclear whether ovariectomy can alter the activity of GSK3b or GSK3a. In fact, GSK3 activity is closely regulated in vivo. For instance, the activity of GSK3b is negatively regulated by phosphorylation of Serine 9 residue and positively regulated by phosphorylation of tyrosine 216 residue (Cross et al. 1995; Bhat et al. 2000; Cohen and Frame 2001) . While our studies indicated that ERb activation can inhibit GSK3b phosphorylation at serine 9, future studies will be necessary to examine other phosphorylation sties of GSK3a and GSK3b in aged female rats following ovariectomy.
While our study indicated GSK3 may have an inhibitory control over tight junction protein expression, the underlying molecular mechanism might involve other signaling molecules. For example, b-catenin is critically regulated by GSK3b, and is involved in regulation of tight junction protein expressions. Studies have shown that GSK3b can phosphorylate b-catenin, resulting in its degradation, and conversely, inactivation of GSK3b lead to accumulation of b-catenin (Angers and Moon 2009). Furthermore, it has been shown that b-catenin can function as a co-transactivator by forming a complex with the lymphoid enhancer factor/T-cell factor family of transcription factors and promote the expression of target genes (Watanabe and Dai 2011) , such as tight junction proteins claudin-1, -2, and -3 (Miwa et al. 2001; Mankertz et al. 2004; Liebner et al. 2008) . Alternatively, b-catenin can interact with adherens junctions to down-regulate Slug, which inhibits the transcription of occludin in epithelial cells (Medici et al. 2006; Wang et al. 2007) . However, whether the expression of claudin-5 or ZO-1 is regulated b-catenin is still not known, particularly in brain endothelial cell tight junctions. Hence, future studies will be important to explore the role of b-catenin in regulation of ischemia-induced BBB disruption in aged female rats following ovariectomy.
Besides the role of GSK3b in regulation of tight junction protein expression, previous studies have also demonstrated that GSK3b is involved in anti-inflammatory effects using in vitro and in vivo models of acute and chronic inflammation (Cross et al. 1995; Jope and Roh 2006; Ramirez et al. 2010) . Specifically, inhibition of GSK3b decreases inflammatory responses in brain endothelial cells (Ramirez et al. 2010) , which likely enhance the stability of the BBB. While our study did not focus on the role of GSK3b in neuroinflammation, previous reports have shown that lack of ovarian function can result in increases in neuroinflammation in aged animals (Benedusi et al. 2012) . Similarly, one of the most prominent changes in the human brain's neuroinflammatory response during aging is the increased and/or poorly regulated production of pro-inflammatory mediators (Franceschi et al. 2000) . In fact, numerous studies have indicated that estrogen plays a critical role in regulating neuroinflammation (Villa et al. 2016) . Thus, it will be necessary to examine whether GSK3b is involved in ER-mediated neuroprotective effects against ischemia-induced BBB disruption via decreasing inflammatory responses in brain endothelial cells in the future.
Our findings also indicated that ERs regulate GSK3b expression in vivo. Specifically, we showed that stimulation of ERb, but not ERa, resulted in decreased expression of GSK3b in the brains of aged female rats following MCAO. While our study did not examine the effects of ERb or ERa activation on GSK3b activity, previous studies have demonstrated that estradiol administration to ovariectomized rats can alter the phosphorylation of GSK3a and GSK3b, which is critical for the activity of GSK3. In fact, multiple signaling pathways may be involved in regulating GSK3 activity. For instance, estradiol may interact with the Insulin/IGF-I pathway in the brain to promote neuronal protection (Duenas et al. 1996; Garcia-Segura et al. 2000; Cardona-Gomez et al. 2001; Quesada and Etgen 2002) , by binding to phosphoinositide 3-kinase, an IGF-I receptor effector (Mendez et al. 2003) . Additionally, it has been shown that estrogen can directly activate Akt (Zhang et al. 2001; Cardona-Gomez et al. 2002; Ivanova et al. 2002a,b) , which in turn inhibits GSK3 activity via phosphorylation on serines 9 and 21 residues (Alessi et al. 1996; Alessi and Cohen 1998; Cohen and Frame 2001; Scheid and Woodgett 2001) . Thus, it is likely that the Akt pathway may be involved in ER-mediated regulation of GSK3 activity in brain endothelial cells. Additionally, it has been found that inhibition of transforming growth factor-b-activated kinase 1 is neuroprotective after focal ischemia, and transforming growth factorb-activated kinase 1 and pGSK-3b interacts to improved stroke outcomes (White et al. 2012; Venna et al. 2015) . Future studies will be important to determine the molecular mechanisms underlying the effects of ER stimulation on GSK3b expression and activity in brain endothelial cells.
In conclusion, our study first demonstrated that aged female rats exhibited increased protein levels of GSK3b in brain cortical areas following ovariectomy, suggesting that estrogen may exert an inhibitory control over GSK3b protein expression. Furthermore, we showed that GSK3 inhibition has protective effects against ischemia-induced BBB disruption. Finally, we reported that ERb is involved in regulating GSK3b expression, and ERb stimulation can increase tight junction protein expression and improve neurological scores in ovariectomized female rats following brain ischemia. Our results suggest that activation of ERb-GSK3b-mediated signaling may protect against brain ischemia-induced BBB disruption.
